Biosyent Inc. · TSXV:RX
Biosyent — Q1 2022 Earnings Presentation
13 slides from Biosyent's earnings presentation, May 18, 2022
Slide 1: Q1 2022 Results
BioSyent Inc. PRESENTED BY: RENÉ GOEHRUM Q1 2022 Results PRESIDENT AND CEO MAY 18, 2022
Slide 2: Disclaimer
Disclaimer This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements
Slide 3: Sales, EBITDA and NIAT
Sales, EBITDA and NIAT Quarter (Q1) ended March 31, 2022 8,000 +22% -5% Total sales flat Q1 ‘22 vs. Q1 ‘21 7,000 +35% adjusting for discontinued brands +35% 6,000 Q1 2022 Sales: +1%* Canadian Pharma 5,000 -50% International Pharma +233% Legacy CAD (000's) 4,000 *+8% on Continuing Canadian 3,000 +18%
Slide 4: Fully Diluted Earnings per Share
Fully Diluted Earnings per Share Quarter NIAT Diluted EPS Q1 2022 $1,587,904 $0.13 Q4 2021 $1,877,804 $0.15 $0.49 - TTM Q3 2021 $1,721,320 $0.13 Q2 2021 $1,018,074 $0.08 Q1 2021 $1,664,368 $0.13 Q4 2020 $665,702 $0.05 $0.31 Q3 2020 $955,909 $0.07 Q2 2020 $722,206 $0.06 4
Slide 5: Q1 2022 Sales Summary
Q1 2022 Sales Summary Q1 ‘22 Q1 ‘22 vs. Sales ($) Q1 ’21 (%) Canadian Pharma ($) $6,319k +1% FeraMAX® (units) +4% +8% Sales Growth on Continuing Canadian Pharma Brands RepaGyn® (units) +16% Tibella® (units) +66% Decline in Combogesic® due to Combogesic® (units) (5%) comparison with initial launch in
Slide 6: FeraMAX® #1 for 7th Consecutive Year
FeraMAX® #1 for 7th Consecutive Year § Most recommended iron supplement in Canada by both pharmacists and physicians § Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2022 Survey on OTC Counselling and Recommendations § BioSyent continues to innovate and expand FeraMAX®
Slide 7: A New Platform for FeraMAX® Product Innovation
A New Platform for FeraMAX® Product Innovation § FeraMAX® Pd platform introduced in October 2020 § Patented delivery system based on Polydextrose Iron Complex (“PDIC”) § Foundation for future product developments § FeraMAX® Pd Therapeutic 150 launched Nov 2020 § FeraMAX® Pd Powder 15 launched Oct 20
Slide 8: Growth Drivers
Growth Drivers FeraMAX® Pd Platform – Life Cycle Strategy Investments In: • Additional products in development Field Salesforce • Next product launch ~Q4 2022 HRT agent for menopause therapy • Launched July 2020 Marketing Resources First formulation combining acetaminophen + ibuprofen for pain relie
Slide 9: Cash Balance & Return on Equity (RoE)
Cash Balance & Return and Equity (“RoE”) 30,000 25% • Zero Long-term Debt 21% • Mar 31/22 Working Capital of 28,000 19% 26,844 20% $30,524k 26,000 15% 15% • TTM Mar 31/22 Cash from 24,024 Operations = $5,484k 24,000 CAD (000's) RoE % 10% • TTM Mar 31/22 RoE Net of 22,000 Cash and ST investments = 21
Slide 10: Capital Allocation linked to Strategy
Capital Allocation linked to Strategy First use of capital is to generate revenue growth & portfolio diversification Cash: $26.8M Growth & Diversification Debt: $0M Excess capital may also be returned to shareholders TSXV: RX 10
Slide 11: Normal Course Issuer Bid (NCIB)
Normal Course Issuer Bid (NCIB) Fully Diluted No. Shares Shares Period Repurchased Outstanding Dec 10, 2018 14,675,307 129,700 shares NCIB Purchases: Dec 10, 2018 – present (1,905,925) purchased Jan 1 – May 13, As of May 13, 2022 12,816,212 2022 §13% reduction in f/d shares since commencing NCIB 1 i
Slide 12: Stock Information
Stock Information As at May 13, 2022 Exchange & Trading Symbol 0% TSXV: RX May 13, 2022 Closing Stock Price (CAD) $8.45 52 Week Hi/Low: $10.00 / $6.76 Issued Common Shares: 12,634,161 Treasury – RSU Shares in Trust (226,100) Outstanding Common Shares: 12,408,061 Options Outstanding 164,475 RSUs Outs
Slide 13: Thank you.
Profitable. Demonstrated financial durability. Well positioned. Growth assets. Focused on long term growth and Total Shareholder Return. Thank you. 13